Repurposing celecoxib as a topical antimicrobial agent

Frontiers in Microbiology

Volumn 6, Issue JUL, 2015, Pages

  Thangamani, Shankar ^a   Younis, Waleed ^a   Seleem, Mohamed N ^a  

^a PURDUE UNIVERSITY   (United States)

Author keywords

Anti inflammatory; Antimicrobial resistance; Celecoxib; Repurposing; Skin infection

Indexed keywords

CELECOXIB; CLINDAMYCIN; DAPTOMYCIN; FUSIDIC ACID; GENTAMICIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; LINEZOLID; PSEUDOMONIC ACID; RETAPAMULIN; TUMOR NECROSIS FACTOR ALPHA; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACILLUS; BACTERIAL COUNT; BACTERIAL SKIN DISEASE; BACTERIAL STRAIN; BROTH DILUTION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG REPOSITIONING; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; LISTERIA; MEMBRANE PERMEABILITY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MYCOBACTERIUM; NONHUMAN; PROTEIN SYNTHESIS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS; TOXICITY ASSAY;

ACINETOBACTER; ANIMALIA; BACILLUS (BACTERIUM); BACTERIA (MICROORGANISMS); CAENORHABDITIS ELEGANS; LISTERIA; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MYCOBACTERIUM; NEGIBACTERIA; POSIBACTERIA; PSEUDOMONAS; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS;

EID: 84938850641     PISSN: None     EISSN: 1664302X     Source Type: Journal    
DOI: 10.3389/fmicb.2015.00750     Document Type: Article

References (63)

1. Alajlouni, R. A., and Seleem, M. N. (2013). Targeting listeria monocytogenes rpoA and rpoD genes using peptide nucleic acids. Nucleic Acid Ther. 23, 363-367. doi: 10.1089/nat.2013.0426
2. Annamanedi, M., and Kalle, A. M. (2014). Celecoxib sensitizes Staphylococcus aureus to antibiotics in macrophages by modulating SIRT1. PLoS ONE 9:e99285. doi: 10.1371/journal.pone.0099285
3. Aryee, A., and Price, N. (2015). Antimicrobial stewardship-can we afford to do without it?. Br. J. Clin. Pharmacol. 79, 173-181. doi: 10.1111/bcp.12417
4. Ashburn, T. T., and Thor, K. B. (2004). Drug repositioning: identifying and developing new uses for existing drugs. Nat. Rev. Drug Discov. 3, 673-683. doi: 10.1038/nrd1468
5. Bensen, W. G. (2000). Antiinflammatory and analgesic efficacy of COX-2 specific inhibition: from investigational trials to clinical experience. J. Rheumatol. Suppl. 60, 17-24.
6. Brynildsen, M. P., Winkler, J. A., Spina, C. S., Macdonald, I. C., and Collins, J. J. (2013). Potentiating antibacterial activity by predictably enhancing endogenous microbial ROS production. Nat. Biotechnol. 31, 160-165. doi: 10.1038/nbt.2458
7. Centers for Disease Control and Prevention [CDC] (ed.). (2013). Antibiotic Resistance Threats in the United States, 2013. Atlanta: CDC.
8. Chambers, H. F., and Deleo, F. R. (2009). Waves of resistance: Staphylococcus aureus in the antibiotic era. Nat. Rev. Microbiol. 7, 629-641. doi: 10.1038/nrmicro2200
9. Chiu, H. C., Lee, S. L., Kapuriya, N., Wang, D., Chen, Y. R., Yu, S. L., et al. (2012). Development of novel antibacterial agents against methicillin-resistant Staphylococcus aureus. Bioorg. Med. Chem. 20, 4653-4660. doi: 10.1016/j.bmc.2012.06.018
10. Chiu, H. C., Yang, J., Soni, S., Kulp, S. K., Gunn, J. S., Schlesinger, L. S., et al. (2009). Pharmacological exploitation of an off-target antibacterial effect of the cyclooxygenase-2 inhibitor celecoxib against Francisella tularensis. Antimicrob. Agents Chemother. 53, 2998-3002. doi: 10.1128/AAC.00048-09
11. Cho, J. S., Pietras, E. M., Garcia, N. C., Ramos, R. I., Farzam, D. M., Monroe, H. R., et al. (2010). IL-17 is essential for host defense against cutaneous Staphylococcus aureus infection in mice. J. Clin. Invest. 120, 1762-1773. doi: 10.1172/JCI40891
12. Cho, J. S., Zussman, J., Donegan, N. P., Ramos, R. I., Garcia, N. C., Uslan, D. Z., et al. (2011). Noninvasive in vivo imaging to evaluate immune responses and antimicrobial therapy against Staphylococcus aureus and USA300 MRSA skin infections. J. Invest. Dermatol. 131, 907-915. doi: 10.1038/jid.2010.417
13. Chong, C. R., and Sullivan, D. J. (2007). New uses for old drugs. Nature 448, 645-646. doi: 10.1038/448645a
14. Cowin, A. J., Hatzirodos, N., Rigden, J., Fitridge, R., and Belford, D. A. (2006). Etanercept decreases tumor necrosis factor-alpha activity in chronic wound fluid. Wound Repair Regen. 14, 421-426. doi: 10.1111/j.1743-6109.2006.00141.x
15. Davis, S. L., Perri, M. B., Donabedian, S. M., Manierski, C., Singh, A., Vager, D., et al. (2007). Epidemiology and outcomes of community-associated methicillin-resistant Staphylococcus aureus infection. J. Clin. Microbiol. 45, 1705-1711. doi: 10.1128/JCM.02311-06
16. Diep, B. A., Carleton, H. A., Chang, R. F., Sensabaugh, G. F., and Perdreau-Remington, F. (2006). Roles of 34 virulence genes in the evolution of hospital-and community-associated strains of methicillin-resistant Staphylococcus aureus. J. Infect. Dis. 193, 1495-1503. doi: 10.1086/503777
17. Diep, B. A., Equils, O., Huang, D. B., and Gladue, R. (2012). Linezolid effects on bacterial toxin production and host immune response: review of the evidence. Curr. Ther. Res. Clin. Exp. 73, 86-102. doi: 10.1016/j.curtheres.2012.04.002
18. Dobie, D., and Gray, J. (2004). Fusidic acid resistance in Staphylococcus aureus. Arch. Dis. Child. 89, 74-77. doi: 10.1136/adc.2003.019695
19. Donath, M. Y. (2014). Targeting inflammation in the treatment of type 2 diabetes: time to start. Nat. Rev. Drug Discov. 13, 465-476. doi: 10.1038/nrd4275
20. Eming, S. A., Krieg, T., and Davidson, J. M. (2007). Inflammation in wound repair: molecular and cellular mechanisms. J. Invest. Dermatol. 127, 514-525. doi: 10.1038/sj.jid.5700701
21. Farrell, D. J., Castanheira, M., and Chopra, I. (2011). Characterization of global patterns and the genetics of fusidic acid resistance. Clin. Infect. Dis. 52(Suppl. 7), S487-S492. doi: 10.1093/cid/cir164
22. Fischbach, M. A., and Walsh, C. T. (2009). Antibiotics for emerging pathogens. Science 325, 1089-1093. doi: 10.1126/science.1176667
23. Fournier, B., and Philpott, D. J. (2005). Recognition of Staphylococcus aureus by the innate immune system. Clin. Microbiol. Rev. 18, 521-540. doi: 10.1128/CMR.18.3.521-540.2005
24. Frampton, J. E., and Keating, G. M. (2007). Celecoxib: a review of its use in the management of arthritis and acute pain. Drugs 67, 2433-2472. doi: 10.2165/00003495-200767160-00008
25. Gordon, R. J., and Lowy, F. D. (2008). Pathogenesis of methicillin-resistant Staphylococcus aureus infection. Clin. Infect. Dis. 46(Suppl. 5), S350-S359. doi: 10.1086/533591
26. Hu, Y., and Coates, A. R. (2013). Enhancement by novel anti-methicillin-resistant Staphylococcus aureus compound HT61 of the activity of neomycin, gentamicin, mupirocin and chlorhexidine: in vitro and in vivo studies. J. Antimicrob. Chemother. 68, 374-384. doi: 10.1093/jac/dks384
27. Huang, L., Dai, T., Xuan, Y., Tegos, G. P., and Hamblin, M. R. (2011). Synergistic combination of chitosan acetate with nanoparticle silver as a topical antimicrobial: efficacy against bacterial burn infections. Antimicrob. Agents Chemother. 55, 3432-3438. doi: 10.1128/AAC.01803-10
28. Jialal, I., Miguelino, E., Griffen, S. C., and Devaraj, S. (2007). Concomitant reduction of low-density lipoprotein-cholesterol and biomarkers of inflammation with low-dose simvastatin therapy in patients with type 1 diabetes. J. Clin. Endocrinol. Metab. 92, 3136-3140. doi: 10.1210/jc.2007-0453
29. Kalle, A. M., and Rizvi, A. (2011). Inhibition of bacterial multidrug resistance by celecoxib, a cyclooxygenase-2 inhibitor. Antimicrob. Agents Chemother. 55, 439-442. doi: 10.1128/AAC.00735-10
30. Khanna, S., Biswas, S., Shang, Y., Collard, E., Azad, A., Kauh, C., et al. (2010). Macrophage dysfunction impairs resolution of inflammation in the wounds of diabetic mice. PLoS ONE 5:e9539. doi: 10.1371/journal.pone.0009539
31. King, M. D., Humphrey, B. J., Wang, Y. F., Kourbatova, E. V., Ray, S. M., and Blumberg, H. M. (2006). Emergence of community-acquired methicillin-resistant Staphylococcus aureus USA 300 clone as the predominant cause of skin and soft-tissue infections. Ann. Intern. Med. 144, 309-317. doi: 10.7326/0003-4819-144-5-200603070-00005
32. Kresken, M., Hafner, D., Schmitz, F. J., Wichelhaus, T. A., and Paul-Ehrlich-Society For, C. (2004). Prevalence of mupirocin resistance in clinical isolates of Staphylococcus aureus and Staphylococcus epidermidis: results of the antimicrobial resistance surveillance study of the paul-ehrlich-society for chemotherapy, 2001. Int. J. Antimicrob. Agents 23, 577-581. doi: 10.1016/j.ijantimicag.2003.11.007
33. Kumar, V., Kaur, K., Gupta, G. K., Gupta, A. K., and Kumar, S. (2013). Developments in synthesis of the anti-inflammatory drug, celecoxib: a review. Recent Pat. Inflamm. Allergy Drug Discov. 7, 124-134. doi: 10.2174/1872213X11307020004
34. McCormack, P. L. (2011). Celecoxib: a review of its use for symptomatic relief in the treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis. Drugs 71, 2457-2489. doi: 10.2165/11208240-000000000-00000
35. McFarland, M. M., Scott, E. M., and Li Wan Po, A. (1994). Time-survival studies for quantifying effects of azlocillin and tobramycin on Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 38, 1271-1276. doi: 10.1128/AAC.38.6.1271
36. McNeil, J. C., Hulten, K. G., Kaplan, S. L., and Mason, E. O. (2011). Mupirocin resistance in Staphylococcus aureus causing recurrent skin and soft tissue infections in children. Antimicrob. Agents Chemother. 55, 2431-2433. doi: 10.1128/AAC.01587-10
37. Mohamed, M. F., Hamed, M. I., Panitch, A., and Seleem, M. N. (2014). Targeting Methicillin-Resistant Staphylococcus aureus with Short Salt-Resistant Synthetic Peptides. Antimicrob. Agents Chemother. 58, 4113-4122. doi: 10.1128/AAC.02578-14
38. Mohamed, M. F., and Seleem, M. N. (2014). Efficacy of short novel antimicrobial and anti-inflammatory peptides in a mouse model of methicillin-resistant Staphylococcus aureus (MRSA) skin infection. Drug Design Dev. Ther. 8, 1979-1983. doi: 10.2147/DDDT.S72129
39. Mohammad, H., Mayhoub, A. S., Cushman, M., and Seleem, M. N. (2015). Anti-biofilm activity and synergism of novel thiazole compounds with glycopeptide antibiotics against multidrug-resistant Staphylococci. J. Antibiot. (Tokyo) 68, 259-266. doi: 10.1038/ja.2014.142
40. Montgomery, C. P., Daniels, M. D., Zhao, F., Spellberg, B., Chong, A. S., and Daum, R. S. (2013). Local inflammation exacerbates the severity of Staphylococcus aureus skin infection. PLoS ONE 8:e69508. doi: 10.1371/journal.pone.0069508
41. Morones-Ramirez, J. R., Winkler, J. A., Spina, C. S., and Collins, J. J. (2013). Silver enhances antibiotic activity against gram-negative bacteria. Sci. Transl. Med. 5:190ra181. doi: 10.1126/scitranslmed.3006276
42. O'Neill, A. J., Bostock, J. M., Moita, A. M., and Chopra, I. (2002). Antimicrobial activity and mechanisms of resistance to cephalosporin P1, an antibiotic related to fusidic acid. J. Antimicrob. Chemother. 50, 839-848. doi: 10.1093/jac/dkf248
43. Okusu, H., Ma, D., and Nikaido, H. (1996). AcrAB efflux pump plays a major role in the antibiotic resistance phenotype of Escherichia coli multiple-antibiotic-resistance (Mar) mutants. J. Bacteriol. 178, 306-308.
44. Pereira, P. A., Trindade, B. C., Secatto, A., Nicolete, R., Peres-Buzalaf, C., Ramos, S. G., et al. (2013). Celecoxib improves host defense through prostaglandin inhibition during Histoplasma capsulatum infection. Mediators Inflamm. 2013:11. doi: 10.1155/2013/950981
45. Rajamuthiah, R., Fuchs, B. B., Conery, A. L., Kim, W., Jayamani, E., Kwon, B., et al. (2015). Repurposing salicylanilide anthelmintic drugs to combat drug resistant Staphylococcus aureus. PLoS ONE 10:e0124595. doi: 10.1371/journal.pone.0124595
46. Randall, C. P., Mariner, K. R., Chopra, I., and O'Neill, A. J. (2013). The target of daptomycin is absent from Escherichia coli and other gram-negative pathogens. Antimicrob. Agents Chemother. 57, 637-639. doi: 10.1128/AAC.02005-12
47. Rangel-Vega, A., Bernstein, L. R., Mandujano-Tinoco, E. A., Garcia-Contreras, S. J., and Garcia-Contreras, R. (2015). Drug repurposing as an alternative for the treatment of recalcitrant bacterial infections. Front. Microbiol. 6:282. doi: 10.3389/fmicb.2015.00282
48. Rioja, I., Bush, K. A., Buckton, J. B., Dickson, M. C., and Life, P. F. (2004). Joint cytokine quantification in two rodent arthritis models: kinetics of expression, correlation of mRNA and protein levels and response to prednisolone treatment. Clin. Exp. Immunol. 137, 65-73. doi: 10.1111/j.1365-2249.2004.02499.x
49. Seybold, U., Kourbatova, E. V., Johnson, J. G., Halvosa, S. J., Wang, Y. F., King, M. D., et al. (2006). Emergence of community-associated methicillin-resistant Staphylococcus aureus USA300 genotype as a major cause of health care-associated blood stream infections. Clin. Infect. Dis. 42, 647-656. doi: 10.1086/499815
50. Sharma-Kuinkel, B. K., Zhang, Y., Yan, Q., Ahn, S. H., Fowler, V. G. Jr. (2013). Host gene expression profiling and in vivo cytokine studies to characterize the role of linezolid and vancomycin in methicillin-resistant Staphylococcus aureus (MRSA) murine sepsis model. PLoS ONE 8:e60463. doi: 10.1371/journal.pone.0060463
51. Stryjewski, M. E., and Corey, G. R. (2014). Methicillin-resistant Staphylococcus aureus: an evolving pathogen. Clin. Infect. Dis. 58(Suppl. 1), S10-S19. doi: 10.1093/cid/cit613
52. Tattevin, P., Diep, B. A., Jula, M., and Perdreau-Remington, F. (2009). Methicillin-resistant Staphylococcus aureus USA300 clone in long-term care facility. Emerg. Infect. Dis. 15, 953-955. doi: 10.3201/eid1506.080195
53. Tenover, F. C., and Goering, R. V. (2009). Methicillin-resistant Staphylococcus aureus strain USA300: origin and epidemiology. J. Antimicrob. Chemother. 64, 441-446. doi: 10.1093/jac/dkp241
54. Tenover, F. C., Mcallister, S., Fosheim, G., Mcdougal, L. K., Carey, R. B., Limbago, B., et al. (2008). Characterization of Staphylococcus aureus isolates from nasal cultures collected from individuals in the United States in 2001 to 2004. J. Clin. Microbiol. 46, 2837-2841. doi: 10.1128/JCM.00480-08
55. Thangamani, S., Mohammad, H., Younis, W., and Seleem, M. N. (2015). Drug repurposing for the treatment of Staphylococcal Infections. Curr. Pharm. Des. 21, 2089-2100. doi: 10.2174/1381612821666150310104416
56. Tindall, E. (1999). Celecoxib for the treatment of pain and inflammation: the preclinical and clinical results. J. Am. Osteopath. Assoc. 99, S13-S17.
57. Tong, S. Y., Bishop, E. J., Lilliebridge, R. A., Cheng, A. C., Spasova-Penkova, Z., Holt, D. C., et al. (2009). Community-associated strains of methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus in indigenous Northern Australia: epidemiology and outcomes. J. Infect. Dis. 199, 1461-1470. doi: 10.1086/598218
58. Vaara, M. (2010). Polymyxins and their novel derivatives. Curr. Opin. Microbiol. 13, 574-581. doi: 10.1016/j.mib.2010.09.002
59. Vaara, M., Siikanen, O., Apajalahti, J., Fox, J., Frimodt-Møller, N., He, H., et al. (2010). A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane. Antimicrob. Agents Chemother. 54, 3341-3346. doi: 10.1128/AAC.01439-09
60. Velkov, T., Deris, Z. Z., Huang, J. X., Azad, M. A., Butler, M., Sivanesan, S., et al. (2013). Surface changes and polymyxin interactions with a resistant strain of Klebsiella pneumoniae. Innate Immun. 20, 350-363. doi: 10.1177/1753425913493337
61. Wallace, H. J., and Stacey, M. C. (1998). Levels of tumor necrosis factor-alpha (TNF-alpha) and soluble TNF receptors in chronic venous leg ulcers-correlations to healing status. J. Invest. Dermatol. 110, 292-296. doi: 10.1046/j.1523-1747.1998.00113.x
62. White, A. R., Comber, K. R., and Sutherland, R. (1980). Comparative bactericidal effects of azlocillin and ticarcillin against Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 18, 182-189. doi: 10.1128/AAC.18.1.182
63. Wilgus, T. A., Vodovotz, Y., Vittadini, E., Clubbs, E. A., and Oberyszyn, T. M. (2003). Reduction of scar formation in full-thickness wounds with topical celecoxib treatment. Wound Repair Regen. 11, 25-34. doi: 10.1046/j.1524-475X.2003.11106.x